Literature DB >> 20373093

Experimental models to study varicella-zoster virus infection of neurons.

Megan Steain1, Barry Slobedman, Allison Abendroth.   

Abstract

Varicella zoster virus (VZV) infection results in the establishment of latency in human sensory neurons. Reactivation of VZV leads to herpes zoster which can be followed by persistent neuropathic pain, termed post-herpetic neuralgia (PHN). Humans are the only natural host for VZV, and the strict species specificity of the virus has restricted the development of an animal model of infection which mimics all phases of disease. In order to elucidate the mechanisms which control the establishment of latency and reactivation as well as the effect of VZV replication on neuronal function, in vitro models of neuronal infection have been developed. Currently these models involve culturing and infecting dissociated human fetal neurons, with or without their supporting cells, an intact explant fetal dorsal root ganglia (DRG) model, neuroblastoma cell lines and rodent neuronal cell models. Each of these models has distinct advantages as well as disadvantages, and all have contributed towards our understanding of VZV neuronal infection. However, as yet none have been able to recapitulate the full virus lifecycle from primary infection to latency through to reactivation. The development of such a model will be a crucial step towards advancing our understanding of the mechanisms involved in VZV replication in neuronal cells, and the design of new therapies to combat VZV-related disease.

Entities:  

Mesh:

Year:  2010        PMID: 20373093     DOI: 10.1007/82_2010_15

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  10 in total

1.  Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells.

Authors:  Jenna Christensen; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Molecular mechanisms of varicella zoster virus pathogenesis.

Authors:  Leigh Zerboni; Nandini Sen; Stefan L Oliver; Ann M Arvin
Journal:  Nat Rev Microbiol       Date:  2014-02-10       Impact factor: 60.633

3.  The Current State of Vaccine Development for Ocular HSV-1 Infection.

Authors:  D J Royer; A Cohen; Djj Carr
Journal:  Expert Rev Ophthalmol       Date:  2015-04-01

Review 4.  Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy.

Authors:  Barry T Rouse; D Scott Schmid
Journal:  Viruses       Date:  2022-04-21       Impact factor: 5.818

5.  Retrograde axonal transport of VZV: kinetic studies in hESC-derived neurons.

Authors:  Sergei Grigoryan; Paul R Kinchington; In Hong Yang; Anca Selariu; Hua Zhu; Michael Yee; Ronald S Goldstein
Journal:  J Neurovirol       Date:  2012-08-24       Impact factor: 2.643

6.  Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models.

Authors:  Paul R Kinchington; William F Goins
Journal:  J Neurovirol       Date:  2011-12-28       Impact factor: 3.739

Review 7.  Coevolution pays off: Herpesviruses have the license to escape the DNA sensing pathway.

Authors:  Markus Stempel; Baca Chan; Melanie M Brinkmann
Journal:  Med Microbiol Immunol       Date:  2019-02-25       Impact factor: 4.148

8.  A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61.

Authors:  Daniel P Depledge; Werner J D Ouwendijk; Tomohiko Sadaoka; Shirley E Braspenning; Yasuko Mori; Randall J Cohrs; Georges M G M Verjans; Judith Breuer
Journal:  Nat Commun       Date:  2018-03-21       Impact factor: 14.919

Review 9.  Molecular Aspects of Varicella-Zoster Virus Latency.

Authors:  Daniel P Depledge; Tomohiko Sadaoka; Werner J D Ouwendijk
Journal:  Viruses       Date:  2018-06-28       Impact factor: 5.048

10.  An efficient method for dorsal root ganglia neurons purification with a one-time anti-mitotic reagent treatment.

Authors:  Rui Liu; Gou Lin; Hanpeng Xu
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.